Evidence map›Paper›PMID 40607075›Full record

ArticleThe Lancet regional health. Western Pacific2025

Epidemiology of hand, foot, and mouth disease outbreaks before and during availability of EV-A71 vaccine in China's mainland: analysis of outbreak surveillance data from 2011 to 2023.

Fengfeng Liu, Yao Yi, Yang Song, Xiyu Zhang, Tiancheng Xie, Yanzhe Liu, Yucun Chen, Siping Huang, Jie Zhang, Yanping Zhang and 2 more

Abstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Disease burden of non-polio enterovirus-associated meningitis in children in G20 countries: an analysis based on GBD data and projections to 2050.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Serial passagingFrontiers in cellular and infection microbiology · 2026
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fengfeng LiuDepartment of Health Policy and Management, School of Public Health, Peking University, No. 38, Xueyuan Road, Haidian District, Beijing, 100191, PR China.
Yao YiGuangdong Provincial Center for Disease Control and Prevention, No.160, Qunxian Road, Panyu District, Guangzhou, Guangdong Province, 511430, PR China.
Yang SongDivision of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, PR China.
Xiyu ZhangDepartment of Laboratorial Science and Technology, School of Public Health, Peking University, No. 38, Xueyuan Road, Haidian District, Beijing, 100191, PR China.
Tiancheng XieDepartment of Laboratorial Science and Technology, School of Public Health, Peking University, No. 38, Xueyuan Road, Haidian District, Beijing, 100191, PR China.
Yanzhe LiuDivision of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, PR China.
Yucun ChenDalian Prefectural Center for Disease Control and Prevention, No. 151 Yueling West Street, Ganjingzi District, Dalian City, Liaoning Province, 116037, PR China.
Siping HuangNanchang Prefectural Center for Disease Control and Prevention, No. 833 Lijing Road, Honggutan District, Nanchang City, Jiangxi Province, 330038, PR China.
Jie ZhangNanning Prefectural Center for Disease Control and Prevention, Emergency Response Office, No. 55 Xiangzhu Avenue, Xingning District, Nanning City, Guangxi Zhuang Autonomous Region, 530021, PR China.
Yanping ZhangDivision of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, PR China.
Zhaorui ChangDivision of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, PR China.
Fuqiang CuiDepartment of Health Policy and Management, School of Public Health, Peking University, No. 38, Xueyuan Road, Haidian District, Beijing, 100191, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hand, foot, and mouth disease is a common contagious illness of childhood that causes a heavy disease burden in China's mainland. There are three enterovirus A71 (EV-A71) vaccines licensed and used in China since 2016. Our study describes changes in epidemiological characteristics of HFMD outbreaks following EV-A71 vaccine introduction. Methods: Using HFMD outbreak data notified to China CDC during 2011-2023, we compared characteristics of HFMD outbreaks before and after EV-A71 vaccine licensure and availability. We determined risk factors associated with outbreak size with a multivariate regression model and explored county-level patterns of outbreak clusters using local indicators of spatial association (Anselin Local Moran's Findings: During 2011-2023, there were 2838 HFMD outbreaks reported with more than ten cases each that were included in our study. There were 53,958 HFMD cases and 17 deaths in the included outbreaks. The median attack rate was 0.07% (IQR = 0.04%-0.13%) and the median outbreak duration was 14 days (IQR = 9-21). Outbreaks began before school seasons started and peaked during weeks 16-25; most (87.95%) occurred in kindergartens, followed by primary or secondary schools (6.69%). Coxsackievirus A16 (CV-A16) caused 54.94% of the HFMD outbreaks, EV-A71 caused 19.77%, CV-A6 caused 8.99%, CV-A10 caused 0.53%, and other enteroviruses caused 15.76%. After EV-A71 vaccine was introduced into the market as a non-National Immunization Program (NIP) vaccine, the proportion of outbreaks caused by EV-A71 declined to 2.93% in the southern provinces and 4.84% in the northern provinces, and CV-A16, CV-A6, CV-A10, and other enteroviruses increased in proportion. Before EV-A71 vaccine availability, high-high clusters occurred in 37 counties of nine provinces, expanding to 117 counties of nine provinces after vaccine introduction, mainly into southern provinces. Interpretation: After EV-A71 vaccine was introduced to the market in China, fewer HFMD outbreaks were caused by EV-A71 and more were caused by CV-A16, CV-A6, and CV-A10. The changes of spectrum for HFMD and expansion of outbreaks hotspots associated with vaccine introduction calls for multi-enterovirus vaccine development for controlling HFMD outbreaks. Funding: Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education; Prevention and Control Mechanisms for Major Infectious Diseases in the Cyber-Physical-Social Tri-Space (2023YFC2308702).

Indexed as

Enterovirus A 71 vaccineEpidemiologyHand, foot, and mouth diseaseOutbreaks

Identifiers

PMID40607075
PMCPMC12219462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.